Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

[News]

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

More... (http://www.news-medical.net/news/20110203/Enrollment-stopped-in-one-of-two-global-necitumumab-Phase-III-studies-in-NSCLC.aspx)